Other languages Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Market Closed - Toronto S.E. Other stock markets 15:50:24 2024-06-28 EDT			5-day change	1st Jan Change
0.21 ^CAD	+10.53%		+13.51%	+20.00%

06-20	Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy	CI
06-12	Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy	06-20
Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy	06-12
Theralase Technologies Inc. Announces Ruvidar Enhances Efficacy of Cancer Drug	06-10
Theralase Technologies Inc. Successfully Destroys Lung Cancer	06-06
Theralase® Technology Effective in Virus Inactivation	06-04
Theralase Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	04-05
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	01-15
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study	23-10-23
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study	23-10-16
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy	23-10-05
Theralase®? Technologies Inc. Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer	23-09-27
Theralase Technologies First-Half Loss Narrows Even as Revenue Declined by 23%	23-08-29
Theralase Technologies Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29
Theralase Technologies Inc. Announces Appointment of Kaouthar Lbiati as Independent Director	23-06-06
Theralase Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29
Theralase Technologies Inc. Announces Chief Executive Officer Changes	23-05-24
Theralase® Provides Update on Phase II Bladder Cancer Study	23-05-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Other languages

Filters